A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Dimethyl (TECFIDERA)

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and a....

First FDA approval2013-03-27
Generic availableYes · 13 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$320.0M in CY2024 Part D spend111K claims · 18K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.518/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.648
Across all dosage forms in distribution.
Highest NADAC
$0.890
Range is tight.
Plans with PA
612 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Dimethyl used for?

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and a....

Is there a generic for Dimethyl?

Yes. 26 ANDAs filed at FDA, 13 generic manufacturers currently shipping.

How much does my plan pay for Dimethyl?

Across 329 Part D plans, Dimethyl averages $0.648/unit (NADAC). Lowest available: $0.518/unit. Highest in distribution: $0.890/unit.

Is Dimethyl on the FDA shortage list?

No. Dimethyl is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Drug class1 alternative in D1
01
Dimethyl-Fumarate
Brand: DIMETHYL FUMARATE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.